<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01277263</url>
  </required_header>
  <id_info>
    <org_study_id>NIH/LAMMP-2010-7789</org_study_id>
    <nct_id>NCT01277263</nct_id>
  </id_info>
  <brief_title>Predicting Pathological Response Within the 1st Week of Chemotherapy Using Diffuse Optical Spectroscopic Imaging</brief_title>
  <official_title>Predicting Pathological Response Within the 1st Week of Neoadjuvant Chemotherapy Using Functional Parameters Measured With Diffuse Optical Spectroscopic Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beckman Laser Institute University of California Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women with Breast Cancer who do not respond to chemotherapy may undergo months of treatment&#xD;
      with little or no change in tumor size or overall outcome.&#xD;
&#xD;
      The Researchers have demonstrated a previously undescribed &quot;metabolic flare&quot; response&#xD;
      observed very early in neoadjuvant treatment in breast cancer patients. The research can&#xD;
      determine that this flare is predictive of overall therapy response and is due to both an&#xD;
      inflammatory reaction and cell death induced by cytotoxic therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The researcher can use Diffuse Optical Spectroscopic Imaging device to measure and predict&#xD;
      the markers of the response in the first weeks of chemo-therapy.&#xD;
&#xD;
      The oxyhemoglobin flare response can predictive of overall pathological response to&#xD;
      chemotherapy in human subjects. These vascular changes can indicate the rapid transient&#xD;
      increase and then decrease in oxyhemoglobin concentration in the first hours and days after&#xD;
      therapeutic administration. The magnitude and time course of the flare response in patients&#xD;
      receiving cytotoxic therapy will differ between pathological responders and non-responders.&#xD;
      This oxyhemoglobin &quot;flare response&quot; can be observed In tumors where vascular dynamics are&#xD;
      intact.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Not a Clinical Trial study&#xD;
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>improve treatment prognosis for breast cancer patients</measure>
    <time_frame>12 weeks</time_frame>
    <description>The proposed research plan has the ability to significantly impact breast cancer research and treatment</description>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Diffuse Optical Spectroscopy Imaging</intervention_name>
    <description>Monitoring Breast Cancer during chemo therapy</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      C-Protein serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study population will be selected from an outpatient population of the Cancer Center&#xD;
        Clinic, Beckman Laser Medical Clinic of University of California, Irvine and UCI Pacific&#xD;
        Breast Care. Subjects with the requisite diagnosis of breast cancer will be candidates for&#xD;
        enrollment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female, not pregnant, not breastfeeding&#xD;
&#xD;
          -  greater than 21 years of age but less than 75 years of age&#xD;
&#xD;
          -  will be receiving neoadjuvant chemotherapy for breast cancer as prescribed by their&#xD;
             oncologist&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under 21 year of age&#xD;
&#xD;
          -  Female pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Tromberg, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Beckman Laser Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pacific Breast Care Medical Clinic</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92627</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beckman Laser Institute</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center, UCIMC</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>January 12, 2011</study_first_submitted>
  <study_first_submitted_qc>January 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2011</study_first_posted>
  <last_update_submitted>August 29, 2017</last_update_submitted>
  <last_update_submitted_qc>August 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Beckman Laser Institute and Medical Center</investigator_full_name>
    <investigator_title>Bruce Tromberg, PhD., Director, Beckman Laser Institute and Medical Clinic, Professor, Departments of Biomedical Engineering and Surgery</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

